CION Ameerpet
We would rather tell you this plainly than let you find out later: no ovarian cancer screening has been shown to reduce deaths, even in high-risk women. There is no ovarian equivalent of mammography, and pretending otherwise causes real harm.
Cervical screening works. Breast screening works. Bowel screening works. It is entirely reasonable to assume ovarian screening exists too, and a great many women do — which makes the actual position harder to hear: there is no ovarian cancer screening programme anywhere, for anyone, because none has been shown to save lives.
This is not for want of trying. Very large randomised trials have tested CA-125 and transvaginal ultrasound in the general population, and cohort studies have examined surveillance in high-risk women including BRCA carriers. Screening does find some cancers. What it has not reliably done is find them early enough, or often enough, to reduce the number of women dying of ovarian cancer.
The reason lies in how the disease behaves. High-grade serous ovarian cancer — the commonest and most aggressive type, and the one most associated with BRCA — frequently begins in the fallopian tube and sheds cells across the peritoneal surfaces early, often before there is any localised mass to detect. By the time a scan shows something, disease may already be widespread. It is not that the tests are bad; it is that the window they are looking for may never really open.
Not for the general population and not for high-risk women, because none has shown a mortality benefit.
Very large randomised trials and high-risk cohort studies. The evidence is absence of benefit, not absence of evidence.
High-grade serous disease spreads across the peritoneum early, often before any localised abnormality is visible.
Screening that does not save lives is not neutral — it does harm of its own. Ovarian surveillance produces a substantial number of false positives: an ultrasound finding or a raised CA-125 that leads to further imaging, weeks of severe anxiety, and in a proportion of cases surgery on a healthy ovary that finds nothing wrong. Each of those operations carries real surgical risk and, in a premenopausal woman, a real cost to ovarian reserve. This is precisely why screening is not simply offered on the reasoning that it might help. The harms are certain; the benefit has not been demonstrated. Source: NCCN Ovarian Cancer guidelines; published randomised screening trials.
This distinction matters, because surveillance is not worthless — it is simply not what most people assume it is.
It has not been shown to reduce ovarian cancer deaths, in the general population or in high-risk women. It cannot reliably detect high-grade serous disease before it has spread. It is not equivalent to mammography or cervical screening. A normal result does not mean you do not have ovarian cancer, and it should never be taken as a reason to dismiss new persistent symptoms. It is not a substitute for risk-reducing surgery, and it should not be offered as though it were.
It can find some cancers, including occasionally at an earlier stage. It provides a structured point of contact with a specialist team, which matters more than it sounds — women in surveillance have someone to report symptoms to and a clear route to being seen. And for a woman deliberately deferring surgery to complete her family, it is a reasonable interim measure, provided she understands exactly what she is and is not getting.
The absence of effective screening is exactly why the other measures carry so much weight for high-risk women.
Removing the ovaries and fallopian tubes lowers ovarian cancer risk by around eighty per cent. It is the only intervention with a substantial evidence base for reducing ovarian cancer risk and mortality in high-risk women, and nothing in surveillance approaches it.
It is generally discussed from around 35 to 40 for BRCA1 carriers and 40 to 45 for BRCA2, after childbearing is complete. It brings surgical menopause forward, which is a genuine cost that needs its own planning rather than a footnote. See risk-reducing surgery.
In the absence of screening, knowing the four symptoms that matter — persistent bloating, feeling full quickly, pelvic or abdominal pain, and urinary urgency — and acting on them promptly is genuinely worthwhile. It is not screening and should not be dressed up as such, but the alternative is not noticing.
The threshold that research supports is symptoms that are new within the past year and present on more than twelve days a month. A woman at high hereditary risk should have a considerably lower threshold for reporting these than the general population. See the symptom checklist.
Combined oral contraceptive use is associated with a substantial reduction in ovarian cancer risk, and the effect increases with duration of use and persists for years after stopping. It has been observed in BRCA carriers as well as in the general population.
It is not a substitute for risk-reducing surgery and it carries its own considerations, including a small effect on breast cancer risk that matters particularly for BRCA carriers. But it is a genuine risk-reducing measure and it is worth discussing rather than overlooking. See reducing ovarian cancer risk.
It is worth holding both facts at once: ovarian surveillance does not work, and breast surveillance does. Annual MRI alongside mammography from a younger age detects breast cancer early and reliably in BRCA carriers, and it is a genuine strategy rather than a holding pattern.
This asymmetry frequently confuses people, and it is worth being explicit about, because it explains why the two halves of a BRCA plan look so different. See the BRCA breast-ovarian link.
Because much high-grade serous cancer appears to begin in the fallopian tube, there is interest in removing the tubes earlier while keeping the ovaries — preserving hormone production and delaying surgical menopause — with the ovaries removed later.
This is an area of active study rather than established standard practice, and it should be discussed as such. It is worth asking about if the timing of surgical menopause is your principal concern, but it should not be presented as an equivalent alternative to standard risk-reducing surgery.
Guidance in this area changes, variants are occasionally reclassified, and new evidence emerges. A plan set out five years ago may no longer reflect current practice, and there is no mechanism that automatically updates you.
Remaining in contact with a genetics service means your management is reviewed rather than frozen — and it also means you have a clear route to being seen quickly if symptoms appear, which in the absence of screening is genuinely valuable.
A normal recent scan or CA-125 is not a reason to wait. Surveillance does not rule out disease between appointments.
New within the past year and present on more than 12 days a month. See persistent bloating.
Early satiety — being unable to finish meals you would have managed easily six months ago.
A dull persistent ache present most days, rather than an intermittent cramp. Persistence matters more than severity.
Needing to pass urine more often or urgently, with urine tests that come back clear.
A measurable change in girth, particularly while eating less, warrants prompt imaging rather than waiting for the next scheduled scan.
Losing weight without trying always warrants assessment, whatever your last surveillance result showed.
If you are in surveillance and develop symptoms, contact your team rather than waiting for the next appointment. Between-visit symptoms are exactly what surveillance is worst at catching.
Some women choose surveillance knowingly, and that is a legitimate decision. What it should never be is an unexamined default that quietly substitutes for a conversation about surgery.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. Genetic counselling is in-house at CION, and we will be straightforward about what surveillance does and does not achieve.
It would be easier to offer surveillance without qualification. It feels like doing something, it is straightforward to arrange, and nobody leaves the appointment upset. It is also, in our view, the wrong way to treat a woman who is making one of the more significant decisions of her life on the basis of what she has been told.
So we will say it plainly: surveillance has not been shown to reduce ovarian cancer deaths, and it is not a substitute for risk-reducing surgery. If you choose surveillance while completing your family, or while you decide, that is a legitimate choice and we will support it — provided it is a choice rather than a default that quietly replaced a conversation.
Your first consultation is free and runs to about 45 minutes. Genetic counselling and BRCA and HRD testing are delivered in-house at CION, so risk assessment, testing and the management plan happen with one team. Risk-reducing salpingo-oophorectomy is coordinated with specialist gynaecologic-oncology partner centres and may be billed there. Where cancer does develop, chemotherapy and maintenance therapy are delivered in-house across 35+ centres.
Surveillance is offered honestly, with its limitations stated, rather than as reassurance that happens to be unfounded.
Risk assessment, testing and the management plan handled by one team rather than across several referrals.
The real value of staying in a high-risk service is somewhere to report symptoms and be seen quickly.
Risk-reducing salpingo-oophorectomy is performed at specialist partner centres and may be billed there.
The contrast makes the reasoning clearer than any explanation of ovarian biology alone.
| Cancer | Screening approach | Why it works — or does not |
|---|---|---|
| Cervical | Smear and HPV testing | Detects a precancerous stage that persists for years and can be treated. Genuinely preventive. |
| Bowel | Faecal testing and colonoscopy | Finds and removes precancerous polyps in the same procedure. Preventive as well as detective. |
| Breast | Mammography, plus MRI if high-risk | Superficial organ, imaged in detail; tumours form a localised mass detectable while small. |
| Ovarian | CA-125 and transvaginal ultrasound | Deep organ; high-grade serous disease spreads across the peritoneum before a localised mass appears. |
*The difference is not effort or technology. Cervical and bowel screening work because a treatable precancerous stage exists and lasts. Ovarian cancer has no equivalent detectable window that reliably precedes spread.
No — not for the general population and not for high-risk women, including BRCA carriers. Very large randomised trials have tested CA-125 with transvaginal ultrasound, and cohort studies have examined surveillance in high-risk groups. Screening does find some cancers, but it has not been shown to reduce the number of women dying of ovarian cancer. The obstacle is the biology: high-grade serous disease, the commonest and most aggressive type, frequently begins in the fallopian tube and spreads across the peritoneal surfaces before any localised abnormality is detectable on a scan.
You can, and some high-risk women do, but it is important to understand what it would and would not achieve. CA-125 is not a screening test: it rises in endometriosis, fibroids, pelvic infection, liver disease and even during a normal period, and it can be entirely normal in early ovarian cancer. Annual testing in a woman with no symptoms produces a substantial number of raised results that lead to further imaging, weeks of severe anxiety, and sometimes surgery on a healthy ovary that finds nothing. The harms of that are certain; the benefit has not been demonstrated.
Not pointless, but not what most people assume. It has not been shown to reduce deaths, and it is not a substitute for risk-reducing surgery. What it does offer is a structured point of contact with a specialist team — somewhere to report symptoms and a clear route to being seen quickly, which in the absence of effective screening genuinely matters. For a woman deliberately deferring surgery to complete her family, it is a reasonable interim measure provided she understands exactly what she is getting. What it should never be is an unexamined default that quietly replaces the surgical conversation.
Risk-reducing salpingo-oophorectomy is the intervention with a substantial evidence base, lowering ovarian cancer risk by around eighty per cent — generally discussed from around 35 to 40 for BRCA1 carriers and 40 to 45 for BRCA2, after childbearing. Alongside that, symptom awareness is genuinely worthwhile: know the four symptoms that matter and report them promptly, with a much lower threshold than the general population. Combined oral contraception measurably reduces ovarian cancer risk. And breast surveillance, unlike ovarian, does work and should be running in parallel.
No — contact your team rather than waiting for the next scheduled appointment. Symptoms appearing between visits are precisely what surveillance is worst at catching, and a normal recent result is not a reason to dismiss them. Persistent bloating, feeling full quickly, pelvic pain, new urinary urgency, a genuinely enlarging abdomen or unintended weight loss all warrant prompt assessment in a high-risk woman regardless of when you were last tested. A high-risk service should give you a route to be seen quickly for exactly this reason.
Because of what is available to detect. Cervical screening works because there is a precancerous stage that persists for years and can be treated before cancer develops — the same is true of bowel screening, where polyps are removed during the same procedure. Breast screening works because the breast is superficial and can be imaged in detail, and tumours form a localised mass detectable while small. Ovarian cancer offers neither: the organ sits deep in the pelvis, and high-grade serous disease spreads across the peritoneal surfaces before a localised abnormality reliably appears.
Yes. The first consultation is free and runs to about 45 minutes, and genetic counselling and BRCA and HRD testing are delivered in-house at CION, so risk assessment, testing and the management plan happen with one team rather than across several referrals. We will be straightforward about what surveillance does and does not achieve rather than offering it as unqualified reassurance. Risk-reducing salpingo-oophorectomy is coordinated with specialist gynaecologic-oncology partner centres and may be billed there. Where cancer does develop, chemotherapy and maintenance therapy are delivered in-house across more than 35 centres.